Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review.
Chronic lymphocytic leukemia (CLL) is a disorder with multiple defects leading to an increased susceptibility to infection. Hypogammaglobulinemia is present in about 20% to 70% of patients with CLL. Intravenous immunoglobulin (IVIG) supplementation (400 mg/kg body weight every 3 weeks) prevented bac...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
1991
|
| _version_ | 1797103344030842880 |
|---|---|
| author | Dicato, M Chapel, H Gamm, H Lee, M Ries, F Marichal, S Wirth, C Griffith, H Brennan, V |
| author_facet | Dicato, M Chapel, H Gamm, H Lee, M Ries, F Marichal, S Wirth, C Griffith, H Brennan, V |
| author_sort | Dicato, M |
| collection | OXFORD |
| description | Chronic lymphocytic leukemia (CLL) is a disorder with multiple defects leading to an increased susceptibility to infection. Hypogammaglobulinemia is present in about 20% to 70% of patients with CLL. Intravenous immunoglobulin (IVIG) supplementation (400 mg/kg body weight every 3 weeks) prevented bacterial infections in these patients. An ongoing study is being conducted to compare doses of 250 mg/kg/mo with those of 500 mg/kg/mo in 36 patients included so far. As of this writing, the rate of infection in the two treatment groups was not significantly different, and no substantial loss of protection against bacterial infection was found in the lower-dose group. It seems likely that the lower dose is almost as effective as the standard therapy. If this is so, cost savings would be substantial. |
| first_indexed | 2024-03-07T06:18:48Z |
| format | Conference item |
| id | oxford-uuid:f2016abc-cf1a-49ed-9a04-2934b6a3e5e5 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T06:18:48Z |
| publishDate | 1991 |
| record_format | dspace |
| spelling | oxford-uuid:f2016abc-cf1a-49ed-9a04-2934b6a3e5e52022-03-27T12:00:19ZUse of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:f2016abc-cf1a-49ed-9a04-2934b6a3e5e5Symplectic Elements at Oxford1991Dicato, MChapel, HGamm, HLee, MRies, FMarichal, SWirth, CGriffith, HBrennan, VChronic lymphocytic leukemia (CLL) is a disorder with multiple defects leading to an increased susceptibility to infection. Hypogammaglobulinemia is present in about 20% to 70% of patients with CLL. Intravenous immunoglobulin (IVIG) supplementation (400 mg/kg body weight every 3 weeks) prevented bacterial infections in these patients. An ongoing study is being conducted to compare doses of 250 mg/kg/mo with those of 500 mg/kg/mo in 36 patients included so far. As of this writing, the rate of infection in the two treatment groups was not significantly different, and no substantial loss of protection against bacterial infection was found in the lower-dose group. It seems likely that the lower dose is almost as effective as the standard therapy. If this is so, cost savings would be substantial. |
| spellingShingle | Dicato, M Chapel, H Gamm, H Lee, M Ries, F Marichal, S Wirth, C Griffith, H Brennan, V Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. |
| title | Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. |
| title_full | Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. |
| title_fullStr | Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. |
| title_full_unstemmed | Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. |
| title_short | Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. |
| title_sort | use of intravenous immunoglobulin in chronic lymphocytic leukemia a brief review |
| work_keys_str_mv | AT dicatom useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview AT chapelh useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview AT gammh useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview AT leem useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview AT riesf useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview AT marichals useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview AT wirthc useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview AT griffithh useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview AT brennanv useofintravenousimmunoglobulininchroniclymphocyticleukemiaabriefreview |